American society of clinical oncology statement: toward individualized care for patients with advanced cancer.
Patients with advanced incurable cancer face complex physical, psychological, social, and spiritual consequences of disease and its treatment. Care for these patients should include an individualized assessment of the patient's needs, goals, and preferences throughout the course of illness. Consideration of disease-directed therapy, symptom management, and attention to quality of life are important aspects of quality cancer care. However, emerging evidence suggests that, too often, realistic conversations about prognosis, the potential benefits and limitations of disease-directed therapy, and the potential role of palliative care, either in conjunction with or as an alternative to disease-directed therapy, occur late in the course of illness or not at all. This article addresses the American Society of Clinical Oncology's (ASCO's) vision for improved communication with and decision making for patients with advanced cancer. This statement advocates an individualized approach to discussing and providing disease-directed and supportive care options for patients with advanced cancer throughout the continuum of care. Building on ASCO's prior statements on end-of-life care (1998) and palliative care (2009), this article reviews the evidence for improved patient care in advanced cancer when patients' individual goals and preferences for care are discussed. It outlines the goals for individualized care, barriers that currently limit realization of this vision, and possible strategies to overcome these barriers that can improve care consistent with the goals of our patients and evidence-based medical practice.
Division of Medical Oncology, Duke University Medical Center, Box 3446, Durham, NC 27710, USA. jeffrey.peppercorn@duke.edu
Jeffrey M
JM
Peppercorn
Thomas J
TJ
Smith
Paul R
PR
Helft
David J
DJ
Debono
Scott R
SR
Berry
Dana S
DS
Wollins
Daniel M
DM
Hayes
Jamie H
JH
Von Roenn
Lowell E
LE
Schnipper
D002986:Clinical Trials as Topic; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000592:standards*; D009369:Neoplasms / Q000628:therapy*; D057285:Precision Medicine / Q000379:methods* / Q000592:standards*; D012955:Societies, Medical